Fig. 2
From: Lactobacillus rhamnosus GG cell-free supernatant as a novel anti-cancer adjuvant
Cancer cells treated with LGG-SN show a decrease in cell number not associated with concurrent cell death. A. Immunoblot and densitometry of HT-29, HCT-116, Caco-2, A375 treated with 0% (CTRL), 20%, 50% and 90% v/v LGG-SN, or 0.5 µg/ml Puromycin (positive control treatment). Signal detected for cleaved Caspase 3 (c-Casp-3; 17–19 KDa) and β-Tubulin (normalization control, 48 KDa). B. Trypan blue count for HT-29, HCT-116, Caco-2, A375 treated with 0% (CTRL), 20%, 50% and 90% v/v LGG-SN. Top bar plots: percentage of live (green) and dead (red) cells per each concentration. Bottom plots: cell count (viable green, dead red, total blue) per each concentration of LGG-SN (0% v/v CTRL, 20%, 50% and 90% v/v). C. Trypan blue count for Fibroblasts treated with different concentrations LGG-SN. Top bar plots: percentage of live (green) and dead (red) cells per each concentration. Bottom plots: cell count (viable green, dead red, total blue) per each concentration of LGG-SN. D. Fold change of doubling time of 90% v/v LGG-SN over CTRL 0% v/v treatment. N = 3. Values are presented as Mean ± SD. Statistical significance was analyzed using ordinary one-way ANOVA and two-way ANOVA with Tukey's multiple comparisons test. **p < 0.01; ***p < 0.001; ****p < 0.0001; no asterisk = not significant